Top

Published in:

01-01-2018 | Original Article

Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study

Authors: Jørn Herrstedt, Yvonne Summers, Gedske Daugaard, Thomas B. Christensen, Karin Holmskov, Paul D. Taylor, Gabriel M. Fox, Alexander Molassiotis

Published in: Supportive Care in Cancer | Issue 1/2018

Abstract

Purpose

The purpose of this study was to investigate the antiemetic effect of the dopamine D₂- and dopamine D₃-receptor antagonist, amisulpride, in patients receiving cisplatin-based chemotherapy.

Methods

This dose-finding, non-comparative study investigated the antiemetic effect and safety of increasing doses (2.5, 7.5 and 20 mg) of amisulpride against acute nausea and vomiting in the period 0–24 h after initiation of cisplatin-based chemotherapy. The 20 mg dose was also investigated in combination with the 5-HT₃-receptor antagonist, ondansetron. The primary parameter was complete response (0–24 h), defined as no emesis and no need for rescue antiemetics. Secondary parameters were number of emetic episodes, severity of nausea and time to first emetic episode and start of nausea.

Results

A total of 51 patients were enrolled and evaluable. None of the 10 patients in the 2.5 and 7.5 mg groups obtained a CR. In the 20 mg monotherapy cohort, two of the 18 subjects (11%) had a CR, 3/18 (17%) had no emesis and 12/18 (67%) had no significant nausea. Seven subjects (39%) had no nausea at all (a VAS score < 5 mm). In the combination (ondansetron plus amisulpride) cohort, 19/23 (83%; 90% confidence interval: 65–94%) had a CR and 14/23 (61%) had no nausea at all.

Conclusions

Amisulpride has antiemetic effect against cisplatin-induced acute nausea and vomiting. The effect against nausea is of particular interest. Randomised studies are warranted to further explore the effect and safety of amisulpride.

Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472–4478CrossRef

Kris MG, Gralla RJ, Clark RA, Tyson LB, O'Connell JP, Wertheim MS, Kelsen DP (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379–1384CrossRef

Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482–2494CrossRef

Roila F, Molassiotis M, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M on behalf of the participants of the MASCC/ESMO Consensus Conference Copenhagen 2015 (2016). 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients Ann Oncol 27 (supplement 5):v119-v133

Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the aprepitant protocol 052 study group. J Clin Oncol 21:4112–4119CrossRef

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Ma GJ, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F On behalf of the Aprepitant Protocol 054 Study Group (2003). Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer 97:3090–3098CrossRef

Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla RJ (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340–1346CrossRef

Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 16:1079–1089CrossRef

Moertel CG, Reitemeier RJ (1969) Controlled clinical studies of orally administered antiemetic drugs. Gastroenterology 57:262–268CrossRef

10.

Grunberg SM, Gala KV, Lampenfeld M, Jamin D, Johnson K, Cariffe P, Strych D, Krailo M (1984) Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. J Clin Oncol 2:782–787CrossRef

11.

Roberts WS, Wisniewski BJ, Cavanagh D, Marsden DE (1985) Droperidol as an antiemetic in cis-platinum-induced nausea and vomiting. Oncology 42:42–43CrossRef

12.

Olver IN, Laidlaw CR, Matthews JP, Bishop JF, Hayes AM, Wolf M, Toner GC (1994) A randomised double blind crossover study of domperidone and prochlorperazine suppositories for controlling emesis in outpatients receiving chemotherapy. Eur J Cancer 30A:426–429CrossRef

13.

Stuart-Harris R, Buckman R, Starke I, Wiltshaw E (1983) Chlorpromazine, placebo and droperidol in the treatment of nausea and vomiting associated with cisplatin therapy. Postgrad Med J 59:500–503CrossRef

14.

Herrstedt J, Sigsgaard T, Handberg J, Schousboe BMB, Hansen M, Dombernowsky P (1997) Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer. J Clin Oncol 15:1690–1696CrossRef

15.

Herrstedt J (1998). Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine. Dan Med Bull 45:412-22 (dissertation, University of Copenhagen)

16.

Darmani NA, Zhao W, Ahmad B (1999) The role of D2 and D3 dopamine receptors in the mediation of emesis in Cryptotis parva (the last shrew). J Neural Transm 106:1045–1061CrossRef

17.

Coukell AJ, Spencer CM, Benfield P (1996) Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 6:237–256CrossRef

18.

Kranke P, Eberhart L, Motsch J, Chassard D, Wallenborn J, Diemunsch P, Liu N, Keh D, Bouaziz H, Bergis M, Fox G, Gan TJ (2013) I.V. APD421 (amisulpride) prevents postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled, multicentre trial. Br J Anaesth 111:938–945CrossRef

19.

Spina E, de Leon J (2007) Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 100:4–22CrossRef

20.

Coulouvrat C, Dondey-Nouvel L (1999) Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 14:209–218CrossRef

21.

Taubel J, Ferber G, Fox G, Fernandes S, Lorch U, Camm AJ (2016) Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. Br J Clin Pharmacol. doi:10.1111/bcp.13128 CrossRef

22.

Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10CrossRef

23.

Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL (2009) Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology 205:119–128CrossRef

24.

Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, Amadori D, Bella MA, Gramazio V, Donati D, Ballatori E, Del Favero A (1991) Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675–678CrossRef

25.

Smyth JF, Coleman RE, Nicolson M, Gallmeier WM, Leonard RCF, Cornbleet MA, Allan SG, Upadhyaya BK, Bruntsch U (1991) Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ 303:1423–1426CrossRef

26.

Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pujade-Lauraine E, Paule B, Paes D, Bons J (1990) Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 380332F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816–821CrossRef

27.

Pierce PA, Xie GX, Levine JD, Peroutka SJ (1996) 5-Hydroxytryptamine receptor subtype messenger RNAs in rat peripheral sensory and sympathetic ganglia: a polymerase chain reaction study. Neuroscience 70:553–559CrossRef

28.

Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134–142CrossRef

Title: Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study
Authors: Jørn Herrstedt
Yvonne Summers
Gedske Daugaard
Thomas B. Christensen
Karin Holmskov
Paul D. Taylor
Gabriel M. Fox
Alexander Molassiotis
Publication date: 01-01-2018
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 1/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-017-3825-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

A prospective study of docetaxel-associated pain syndrome

Impact of emotional competence on supportive care needs, anxiety and depression symptoms of cancer patients: a multiple mediation model

A systematic review of dental disease management in cancer patients

Prevalence of hyponatremia in inpatients with incurable and life-limiting diseases and its association with physical symptoms—a retrospective descriptive study

The impact of specialized palliative care on cancer patients’ health-related quality of life: a systematic review and meta-analysis

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim

Keynote webinar | Spotlight on antibody–drug conjugates in cancer